Methadone for cancer-related neuropathic pain: a review of the literature.
Neuropathic pain is commonly seen in cancer patients, either as a direct result of the malignancy or as a consequence of the treatment rendered. In recent years, methadone has been utilized in the treatment of neuropathic pain because of its additional mechanism of action as an NMDA-receptor antagonist. In this paper we discuss the etiology of neuropathic pain in cancer patients, unique properties of methadone, and prior studies on methadone in this patient population. While methadone has been established as a cheap and effective agent in treating cancer pain, specific studies are needed comparing methadone to other opioids in the management of cancer-related neuropathic pain.
Mannino
Rosemarie
R
Division of Hematology/Oncology and Palliative Medicine, Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, USA.
Coyne
Patrick
P
Swainey
Craig
C
Hansen
Lea Ann
LA
Lyckholm
Laurie
L
D000701:Analgesics, Opioid / Q000627:therapeutic use; D000818:Animals; D006801:Humans; D008691:Methadone / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D009422:Nervous System Diseases / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D010146:Pain / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology
D000701:Analgesics, Opioid; D008691:Methadone